Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The U.S. Novo Nordisk Wegovy market size was estimated at USD 7.73 billion in 2025 and is predicted to increase from USD 8.66 billion in 2026 to approximately USD 24.01 billion by 2035, expanding at a CAGR of 12% from 2026 to 2035. Her analysis highlights that the U.S. Novo Nordisk Wegovy market is rapidly expanding due to a growing obese population, expanding MASH application, rising demand for oral formulations, increasing clinical activities, FDA approvals, and competition among key industry players like Eli Lilly and Company, Pfizer Inc., Amgen Inc., Viking Therapeutics, and Structure Therapeutics.
The U.S. Novo Nordisk Wegovy refers to the GLP-1 receptor agonist developed by Novo Nordisk, driving weight loss across the U.S. It consists of three formulations such as once-weekly 2.4mg injection, a once-daily oral tablet, and the higher-dose Wegovy HD 7.2mg injection. Moreover, these formulations are approved by the FDA for indications like chronic weight management, MASH (metabolic dysfunction-associated steatohepatitis), and cardiovascular risk reduction.
As the market research analyst, I interpret that the timeline infographic illustrates Wegovy's three FDA-approved indications from 2021 to 2025. In 2021, Wegovy was approved for chronic weight management (obesity); in 2024, it was approved for cardiovascular risk reduction; and in August 2025, it was approved for MASH (moderate-to-advanced liver fibrosis).
Key Insight:
A differentiated clinical position is achieved by Wegovy across weight management, cardiology, and hepatology simultaneously, as no competing GLP-1 obesity drug has matched this three-indication breadth.
The given infographic stat panel covers Wegovy MASH accelerated approval metrics. On August 15, 2025, Wegovy received FDA accelerated approval for F2–F3 (moderate to advanced), non-cirrhotic fibrosis stages, making it the first GLP-1 receptor agonist approved for MASH and the 2nd overall MASH therapy ranking after Madrigal's Rezdiffra approval in 2024.
Key Insight:
Even after commercial launch with MASH approval, the product is still attached to regulatory risk in this indication, due to which Novo Nordisk must complete a confirmatory trial to demonstrate reduced liver-related clinical events at 240 weeks.
Source: Medscape, “Wegovy Approved for MASH With Fibrosis, No Cirrhosis,” Aug. 18, 2025; FDA NDA 215256/S-024 Approval Letter.
Based on our research, the grouped bar chart compares ESSENCE trial Wegovy and placebo outcomes at week 72. MASH resolution with no worsening of fibrosis for Wegovy and placebo was 63% and 34%, respectively, while fibrosis improvement with no worsening of steatohepatitis for Wegovy and placebo were reported to be 37% and 22%, respectively.
Key Insight:
Wegovy achieved a comparatively rare outcome in MASH drug trials by meeting both co-primary histological endpoints simultaneously, instead of reaching just one, which strengthened its regulatory and clinical position in this new indication.
Source: Healio, “FDA approves Wegovy for certain adults with noncirrhotic MASH,” Aug. 18, 2025.
As per the survey conducted, the infographic stat panel focuses on the oral Wegovy FDA approval metrics. On December 22, 2025, oral Wegovy was granted FDA approval, which demonstrated 16.6% mean weight loss in the OASIS 4 trial, making it the first oral GLP-1 receptor agonist approved for weight management. The product is available in 1.5mg, 4mg, 9mg, and 25mg tablet strengths.
Key Insight:
The previously limited enthusiasm for earlier oral GLP-1 candidates due to central efficacy concerns is waived by this approval, with 16.6% mean weight loss offering Wegovy's efficacy close to the original weekly injection.
Source: Endocrinology Advisor, “FDA Approves Oral Wegovy for Weight Management,” Dec. 26, 2025.
The above-mentioned infographic stat-panel encompasses oral Wegovy U.S. launch metrics. In early January 2026, oral Wegovy 1.5 mg dose manufactured at North Carolina facilities was launched in the U.S. with a starting cash price of $149 per month across select pharmacies and telehealth providers as initial distribution channels.
Key Insight:
The launch of oral Wegovy at $149/month, which contributes to a fraction of typical injectable GLP-1 prices, confirmed that, over near-term per-unit margin, Novo Nordisk is prioritizing rapid market penetration and patient acquisition for the pill.
According to the analysis, the infographic stat panel highlights Wegovy HD accelerated approval metrics. On March 19, 2026, Wegovy HD received FDA approval, making it the first GLP-1 approved under the Commissioner's National Priority Voucher pilot and the highest dose yet approved for a Wegovy injection, which was launched in the U.S. in April 2026.
Key Insight:
As obesity was designated a critical national health priority, the National Priority Voucher pathway accelerated Wegovy HD's review timeline, indicating how future obesity-drug candidates may be reviewed.
Source: Novo Nordisk, SEC Form 6-K, March 19, 2026.
Based on the information gathered, the given bar chart compares STEP UP trial weight-reduction results by treatment arm. The treatment arms placebo, Wegovy 2.4mg (standard dose), and Wegovy HD 7.2mg were reported to have achieved 2.4%, 17.5%, and 20.7% mean weight reduction, respectively, at 72 weeks.
Key Insight:
In a trial of 1,407 adults with obesity, approximately a 3-percentage-point efficacy improvement was observed over the standard dose, which gave physicians a clear clinical rationale to increase appropriate patients to Wegovy HD instead of switching them to a competing product.
As the market research analyst, I interpret that the horizontal bar chart represents the share of Wegovy HD patients achieving more than 25% weight loss. Roughly 33% share of STEP UP participants on Wegovy HD with approximately 1 in 3 achieved 25% or greater weight loss, while all other outcomes contributed to nearly 67% share of STEP UP participants on Wegovy HD.
Key Insight:
The one-in-three rate of surgical-comparable weight loss from a once-weekly injection stands as the strongest efficacy indication reported for any GLP-1 obesity therapy to date, which helps in positioning Wegovy HD by Novo Nordisk against next-generation competitor pipelines.
The given infographic stat panel reflects Wegovy U.S. distribution network metrics. More than 70,000 U.S. pharmacies distribute Wegovy, out of which CVS and Costco are the major retail partners; NovoCare Pharmacy is a direct-to-patient channel, while GoodRx and select telehealth providers are additional access channels.
Key Insight:
Novo Nordisk leverages redundant access pathways, minimizing the risk of channel disruption leading to patient access to Wegovy constraints, by combining traditional retail pharmacy scale with direct-to-patient and telehealth channels simultaneously.
Based on our research, the given horizontal bar chart represents Wegovy U.S. coverage by payer category in 2025. The data covers approximately 55 million Americans with obesity, of which Medicaid-covered patients contributed more than 10 million, and all other covered patients in commercial, Medicare, and other categories were reported to be nearly 45 million.
Key Insight:
The state Medicaid obesity-drug coverage policy varies significantly, and covering 10 million patients, representing a substantial and often overlooked share of Wegovy's market, remains a frequent point of political and budgetary debate as vary significantly.
Source: Towards Healthcare, citing Novo Nordisk company disclosures.
The above-mentioned infographic stat panel covers Wegovy U.S. weekly prescription trend metrics. Novo Nordisk disclosed that for multiple years, Wegovy's prior tenure contributed as the leading U.S. anti-obesity drug, but in early 2025, a competing product was reported to have overtaken Wegovy. Additionally, as of January 23, 2026, weekly U.S. Wegovy prescriptions reached around 230,000.
Key Insight:
Ahead of the multi-formulation 2025–2026 response, Novo Nordisk is proactively managing market and investor expectations around Wegovy's prescription-share trajectory, which is highlighted by mentioning competitive loss rather than omitting it.
Source: Towards Healthcare, citing Novo Nordisk company disclosures.
As per the analysis conducted by Aman, the horizontal bar chart represents companies rated 'Exceptional' across core competitive benchmarks. 5 of 6 categories of Novo Nordisk were rated 'Exceptional', whereas 6 of 6 categories were rated 'Exceptional' for Eli Lilly. 3 of 6 categories were rated 'Exceptional' for Pfizer and Amgen. On the other hand, 1 of 6 categories for Viking Therapeutics and Structure Therapeutics was rated 'Exceptional'.
Key Insight:
With all six benchmarks rated 'Exceptional', Eli Lilly is positioned as the “primary challenger” of Wegovy rather than a secondary threat to Novo Nordisk with one less ‘Exceptional' rating.
Source: Towards Healthcare.
Based on the information gathered by Aman, the infographic stat-panel encompasses data availability and methodology transparency metrics. In 2025, the global branded GLP-1 volume share of 59.6% was disclosed by Novo Nordisk without disclosing precise U.S.-specific dollar market share. Similarly, without mentioning the percentage, the company used “Overtaken” language, leading to a U.S. prescription trend shift and highlighting that the data includes qualitative competitive positioning and not invented percentages.
Key Insight:
The mention of a global volume-share figure and directional U.S. prescription-trend language reflects that the company is comfortable in disclosing favorable global figures over current specific U.S. competitive erosions.
Source: Towards Healthcare, correctly distinguishing disclosed global share data from unavailable U.S.-specific figures.
According to the survey conducted by Aman, the ecosystem infographic represents six pipeline companies competing against Wegovy. Eli Lilly is focusing on oral GLP-1 and next-generation incretins, while Amgen is driven by interest in next-generation obesity therapies. Pfizer and Structure Therapeutics are actively competing for oral GLP-1, while Viking Therapeutics is also contributing by focusing on oral GLP-1/GIP development. Moreover, emerging mechanisms and selective threat are areas of interest for Altimmune.
Key Insight:
Wegovy dominates the market with an advantage following its January 2026 launch, and it is also expected to experience the most contested competition over the next several years, as four of six named competitors are actively pursuing oral formulations in the oral-obesity-drug category.
Source: Towards Healthcare.
As the market research analyst, I interpret that the synthesis infographic illustrates three structural forces shaping Wegovy's 2026 competitive position. August 2025 Wegovy approval opened an entirely new metabolic liver indication, leading to MASH label expansion. In January 2026, an oral formulation breakthrough was recorded with the launch of a pill, which removed the injection barrier to adoption. Recently, in March 2026's higher-efficacy injectable response was recorded with Wegovy HD, which is driving competitive pressure.
Key Insight:
With an aim to defend Wegovy's competitive position in 2025-2026 instead of pursuing incremental change, Novo Nordisk has launched three major label and formulation expansions within an eight-month window, driving an unusually concentrated period of commercial activity.
| Indicator | Value | Source |
| Wegovy indications approved, 2021-2025 | 3 (obesity, CV risk, MASH) | - |
| ESSENCE trial MASH resolution rate (Wegovy vs. placebo) | 63% vs. 34% | Healio, Aug. 2025 |
| OASIS 4 trial mean weight loss, oral Wegovy | 16.6% | Endocrinology Advisor, Dec. 2025 |
| STEP UP trial mean weight loss, Wegovy HD | 20.7% | - |
| U.S. pharmacies/channels carrying Wegovy | 70,000+ | - |
| Americans with obesity reporting Wegovy coverage, 2025 | ~55 million (10M+ via Medicaid) | Towards Healthcare |
The above-mentioned table covers indications and trial results. From 2021 to 2025, 3 Wegovy indications that is obesity, CV risk, and MASH were approved, where the oral Wegovy OASIS 4 trial resulted in 16.6% mean weight loss, while the Wegovy HD STEP UP trial reported 20.7% mean weight loss. The ESSENCE trial MASH resolution rate across Wegovy vs. placebo was noted to be 63% vs. 34%. Moreover, U.S. pharmacies/channels carrying Wegovy exceeded 70,000, while in 2025, Americans with obesity reporting Wegovy coverage totaled roughly 55 million, with more than 10M via Medicaid.
Ten segmentation dimensions such as Formulation, Dosage Strength, Indication, Patient Age, BMI/Patient Profile, Payer, Distribution Channel, Prescriber, Treatment Setting, and Patient Payment/Access Model, along with their market share, CAGR percentages, and recent advancements, are covered in this section.
| Formulation | Recent Advancements | Source |
| Injectable Wegovy (2.4mg standard) | It demonstrated 17.5% mean weight loss in the STEP UP trial (comparator arm) | - |
| Injectable Wegovy HD (7.2mg) |
It was approved in March 2026 It offered 20.7% mean weight loss It was launched in April 2026 |
- |
| Oral Wegovy (tablet) |
It was approved in Dec. 2025 It recorded 16.6% mean weight loss in OASIS It was launched in Jan. 2026 at $149/month starting price |
Endocrinology Advisor; |
The table highlights different types of formulations and their mean weight loss percentage. The injectable Wegovy segment held an 88% share of the market in 2025, driven by its weekly administration, whereas the oral Wegovy segment held the second-largest share of 12% and is expected to expand rapidly during the forecast period, as its daily oral administration removes injection-related barriers.
According to the research conducted, the FDA has approved Wegovy for three distinct indications such as chronic weight management, cardiovascular risk reduction, and MASH. Furthermore, increasing interest in the MASH indication is accelerating its approval, where its pending confirmatory trial results have indicated a reduction in liver-related clinical events at 240 weeks.
As per the survey conducted, Eli Lilly is recognized as the “primary challenger” to Wegovy and contributes to the single most consequential competitive dynamic in the market against Novo Nordisk. Eli Lilly has been rated 'Exceptional' across all its six benchmarked competitive dimensions, where one of its categories has been ranked higher than Novo Nordisk itself, leading to their rivalry.
In April 2026, Wegovy HD was launched across more than 70,000 U.S. pharmacies and channels, involving Costco, GoodRx, CVS, NovoCare Pharmacy, and select telehealth providers, by Novo Nordisk.
Source: PR Newswire, March 2026
On March 19, 2026, under the Commissioner's National Priority Voucher pilot program, Wegovy HD (semaglutide injection 7.2mg) was approved by the FDA, based on its STEP UP trial results demonstrating 20.7% mean weight loss.
Source: PR Newswire; Novo Nordisk SEC Form 6-K, March 2026
In January 2026, the oral Wegovy 1.5 mg dose with a starting cash price of $149/month was launched by Novo Nordisk.
Source: PR Newswire, Jan. 2026
On December 22, 2025, based on the OASIS 4 and SELECT trial programs, Wegovy pill (oral semaglutide 25mg) was granted FDA approval, which made it the first oral GLP-1 receptor agonist approved for weight management.
Source: Endocrinology Advisor; Novo Nordisk press release, Dec. 2025
On August 15, 2025, based on ESSENCE trial results, Wegovy was approved by the FDA for the treatment of noncirrhotic MASH with moderate-to-advanced liver fibrosis, making it the first GLP-1 receptor agonist approved for this indication.
Source: Medscape; Healio; PR Newswire, Aug. 2025
In early 2025, Wegovy, the leading U.S. anti-obesity medication for multiple years, was reported to have been overhauled by a competing GLP-1 product, which was disclosed by Novo Nordisk.
Source: Towards Healthcare
It is the market leader that launched 3 formulations from 2021 to 2026, offers Wegovy for 3 FDA-approved indications, and disclosed its 59.6% global branded GLP-1 volume share in 2025.
It is the primary challenger, rated 'Exceptional' across all 6 benchmarked competitive dimensions.
It is the high-potential emerging competitor, supporting oral GLP-1 development.
It is a high-potential emerging competitor trailing next-generation obesity therapies.
It contributes to the rising challenger, focusing on the oral GLP-1/GIP mechanism.
It is an emerging challenger with a strong interest in the oral GLP-1 mechanism.
It is the federal regulator responsible for the approval of 3 Wegovy indications and formulations from 2021 to 2026, wherein in March 2026 it granted the first GLP-1 National Priority Voucher.
Aditi is a pharmaceutical research expert with strong experience in oral formulation, obesity with metabolic liver diseases, and next-generation incretins markets. She conducted detailed market research, analyzed company data, clinical trends, and industry developments. Based on her comprehensive analysis, the following strategic key takeaways highlight the most important market insights and opportunities.
For Service Providers & CDMOs
For Pharma & Biotech Companies
For Investors & Corporate Strategy Teams
Based on my assessment, the market is expanding rapidly due to growing FDA approvals for different indications. I also anticipate that accelerating clinical trials and their success rates will drive its expansion. Increasing focus on new indications and oral formulations will also fuel market competition. I also see strong growth in collaboration among the major companies, which will create new opportunities.
Payal Rabde led the primary market research, developed the methodology, analyzed trends, segmentation, competition, forecasts, and strategic opportunities, forming the report's analytical foundation.
Aman was responsible for collecting and validating clinical trial data, research publications, company information, partnerships, and other quantitative datasets, strengthening evidence-based analysis and market estimations.
Aditi reviewed the complete research document, performed quality checks, validated findings, refined content, corrected inconsistencies, and finalized the report, ensuring accuracy, clarity, credibility, and publication-ready quality.
By Formulation
By Dosage Strength
By Indication
By Patient Age
By BMI/Patient Profile
By Payer
By Distribution Channel
By Prescriber
By Treatment Setting
By Patient Payment/Access Model
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
